Second-line treatments of advanced non-small-cell lung cancer: New evidence for clinical practice

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 428-429

  Tassinari, D ^a   Drudi, F ^a   Lazzari Agli, L ^a   Tombesi, P ^b   Sartori, S ^b  

^a Department of Oncology   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEFITINIB; ANTINEOPLASTIC AGENT; TAXOID;

ACNE; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL PRACTICE; DIARRHEA; DRUG ERUPTION; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; DISEASE COURSE; DRUG ADMINISTRATION; EVALUATION; LUNG TUMOR; MORTALITY; NOTE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77951889017     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp538     Document Type: Article

References (6)

1. Sekine I, Ichinose Y, Nishiwaki Y et al. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009; 20: 1483-1488.
2. William WN, Gold KA, Kim S. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 2009; 20: 1455-1457.
3. Tassinari D, Scarpi E, Sartori S et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009; 135: 1596-1609.
4. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26: 4244-4252.
5. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-1818.
6. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005; 97: 339-346.